Literature DB >> 20069328

Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis.

Yuji Hirano1, Toshihisa Kojima, Yasuhide Kanayama, Tomone Shioura, Masatoshi Hayashi, Daihei Kida, Atsushi Kaneko, Yoshito Eto, Naoki Ishiguro.   

Abstract

The aim of this study is to investigate the influences of the anti-tumour necrosis factor (TNF) agents infliximab and etanercept on the postoperative recovery of patients with rheumatoid arthritis (RA). We also investigated the effects of biologics on wound healing. Patients with RA were split into a TNF group (n = 39) that underwent 39 operations and were treated with anti-TNF agents, and a non-TNF group (n = 74) that underwent 74 operations and were treated only with conventional disease-modifying antirheumatic drugs. Operations included ankle arthrodesis and total arthroplasty of the hip, knee, elbow, shoulder and ankle. Adverse events (AEs) of surgical wounds, time for complete wound healing, febrile period after operation and recovery parameters after operation (%recovery of haemoglobin (Hb), total protein and albumin at 4 weeks after operation compared with pre-operation levels) were investigated. AEs of surgical wounds occurred in two operations (5.1%) in the TNF group and in five operations (6.8%) in the non-TNF group, but this difference was not statistically significant. There were also no significant differences in the time for complete wound healing and in the length of the febrile period between the two groups. Percentage recovery of Hb was significantly better in the TNF group than in the non-TNF group (96.3% vs. 90.1%, respectively; p < 0.05). These results suggest that the use of anti-TNF agents does not cause specific AEs on surgical wounds after elective orthopaedic operations in RA patients and might improve the percentage recovery of Hb due to its prompt anti-TNF effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069328     DOI: 10.1007/s10067-009-1346-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.

Authors:  S C Talwalkar; D M Grennan; J Gray; P Johnson; M J Hayton
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

2.  Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.

Authors:  D Wendling; J-C Balblanc; A Brousse; A Lohse; G Lehuede; P Garbuio; E Toussirot; B Auge; D Jacques
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

3.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

Review 4.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.

Authors:  Daniel E Furst; Robert Wallis; Michael Broder; David O Beenhouwer
Journal:  Semin Arthritis Rheum       Date:  2006-07-03       Impact factor: 5.532

5.  Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease.

Authors:  M Jongen-Lavrencic; H R Peeters; A Wognum; G Vreugdenhil; F C Breedveld; A J Swaak
Journal:  J Rheumatol       Date:  1997-08       Impact factor: 4.666

6.  Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy.

Authors:  Helen A Papadaki; Heraklis D Kritikos; Vasilis Valatas; Dimitrios T Boumpas; George D Eliopoulos
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

7.  Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration.

Authors:  Ryoichi Mori; Toshikazu Kondo; Tohru Ohshima; Yuko Ishida; Naofumi Mukaida
Journal:  FASEB J       Date:  2002-07       Impact factor: 5.191

8.  Tumor necrosis factor and wound healing.

Authors:  D P Mooney; M O'Reilly; R L Gamelli
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

Review 9.  Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.

Authors:  Ryuji Koike; Tsutomu Takeuchi; Katsumi Eguchi; Nobuyuki Miyasaka
Journal:  Mod Rheumatol       Date:  2007-12-20       Impact factor: 3.023

Review 10.  Recent developments in the anemia of chronic disease.

Authors:  Robert T Means
Journal:  Curr Hematol Rep       Date:  2003-03
View more
  16 in total

Review 1.  Perioperative care for patients with rheumatic diseases.

Authors:  Bharath M Akkara Veetil; Tim Bongartz
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

2.  Rheumatoid Arthritis Does Not Increase Risk of Short-term Adverse Events after Total Knee Arthroplasty: A Retrospective Case-control Study.

Authors:  Zachary J LoVerde; Lisa A Mandl; Beverly K Johnson; Mark P Figgie; Friedrich Boettner; Yuo-Yu Lee; Susan M Goodman
Journal:  J Rheumatol       Date:  2015-05-01       Impact factor: 4.666

Review 3.  Harnessing and modulating inflammation in strategies for bone regeneration.

Authors:  Paschalia M Mountziaris; Patrick P Spicer; F Kurtis Kasper; Antonios G Mikos
Journal:  Tissue Eng Part B Rev       Date:  2011-06-30       Impact factor: 6.389

4.  Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement.

Authors:  Beverly K Johnson; Susan M Goodman; Michael M Alexiades; Mark P Figgie; Ryan T Demmer; Lisa A Mandl
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

Review 5.  Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence.

Authors:  Leslie Goh; Teresa Jewell; Catherine Laversuch; Ash Samanta
Journal:  Rheumatol Int       Date:  2011-07-29       Impact factor: 2.631

6.  [Perioperative use of biologicals in rheumatoid arthritis].

Authors:  F Heldmann; F Dybowski; X Baraliakos; J Braun
Journal:  Z Rheumatol       Date:  2011-01       Impact factor: 1.372

7.  Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing.

Authors:  Gillian S Ashcroft; Moon-Jin Jeong; Jason J Ashworth; Matthew Hardman; Wenwen Jin; Niki Moutsopoulos; Teresa Wild; Nancy McCartney-Francis; Davis Sim; George McGrady; Xiao-Yu Song; Sharon M Wahl
Journal:  Wound Repair Regen       Date:  2011-12-08       Impact factor: 3.617

Review 8.  Centers for Disease Control and Prevention 2017 Guidelines for Prevention of Surgical Site Infections: Review and Relevant Recommendations.

Authors:  K Keely Boyle; Sridhar Rachala; Scott R Nodzo
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

9.  Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs.

Authors:  Masahiro Tada; Kentaro Inui; Yuko Sugioka; Kenji Mamoto; Tadashi Okano; Takuya Kinoshita; Noriaki Hidaka; Tatsuya Koike
Journal:  Clin Rheumatol       Date:  2016-04-29       Impact factor: 2.980

Review 10.  Perioperative management of the patient with rheumatoid arthritis.

Authors:  Megan L Krause; Eric L Matteson
Journal:  World J Orthop       Date:  2014-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.